Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Vultaggio

Showing results (51-60 of 137) with videos related to

Pageof 14
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|March 11, 2011
The TLR7 ligand 9-benzyl-2-butoxy-8-hydroxy adenine inhibits IL-17 response by eliciting IL-10 and IL-10-inducing cytokinesAlessandra Vultaggio, Francesca Nencini, Sara Pratesi, et al.
Journal of Neurovirology|January 28, 2012
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximabSimone Giannecchini, Valeria Clausi, Alessandra Vultaggio, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|October 15, 2024
Effects of Mepolizumab in the treatment of type 2 CRSwNP: a real-life clinical studyPietro Orlando, Emanuele Vivarelli, Alberto Minzoni, et al.
Allergy, Asthma & Immunology Research|July 9, 2020
Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With PolyangiitisAlessandra Vultaggio, Francesca Nencini, Susanna Bormioli, et al.
Frontiers in Immunology|January 29, 2019
T Cell Response to Infliximab in Exposed Patients: A Longitudinal AnalysisSara Pratesi, Francesca Nencini, Francesca Grosso, et al.
Expert Review of Respiratory Medicine|December 13, 2025
Traditional biomarkers and clinical hallmarks in the frame of epithelial driven airways inflammationMarco Caminati, Marco Zurlo, Giuseppe Guida, et al.
The Journal of Allergy and Clinical Immunology|July 20, 2010
Impaired TH2 response in patients with Vav1-deficient common variable immunodeficiency with T-cell defectsNagaja Capitani, Amedeo Amedei, Silvia Rossi Paccani, et al.
European Journal of Heart Failure|July 11, 2006
Tako-Tsubo-like syndrome during anaphylactic reactionAlessandra Vultaggio, Andrea Matucci, Stefano Del Pace, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|February 3, 2022
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experienceAndrea Matucci, Emanuele Vivarelli, Susanna Bormioli, et al.
Frontiers in Immunology|June 14, 2018
Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's SyndromeAndrea Matucci, Francesco Liotta, Emanuele Vivarelli, et al.
Pageof 14

Showing results (51-60 of 137) with videos related to

Sort By:
Pageof 14
Journal of Immunology (Baltimore, Md. : 1950)|March 11, 2011
The TLR7 ligand 9-benzyl-2-butoxy-8-hydroxy adenine inhibits IL-17 response by eliciting IL-10 and IL-10-inducing cytokinesAlessandra Vultaggio, Francesca Nencini, Sara Pratesi, et al.
Journal of Neurovirology|January 28, 2012
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximabSimone Giannecchini, Valeria Clausi, Alessandra Vultaggio, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|October 15, 2024
Effects of Mepolizumab in the treatment of type 2 CRSwNP: a real-life clinical studyPietro Orlando, Emanuele Vivarelli, Alberto Minzoni, et al.
Allergy, Asthma & Immunology Research|July 9, 2020
Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With PolyangiitisAlessandra Vultaggio, Francesca Nencini, Susanna Bormioli, et al.
Frontiers in Immunology|January 29, 2019
T Cell Response to Infliximab in Exposed Patients: A Longitudinal AnalysisSara Pratesi, Francesca Nencini, Francesca Grosso, et al.
Expert Review of Respiratory Medicine|December 13, 2025
Traditional biomarkers and clinical hallmarks in the frame of epithelial driven airways inflammationMarco Caminati, Marco Zurlo, Giuseppe Guida, et al.
The Journal of Allergy and Clinical Immunology|July 20, 2010
Impaired TH2 response in patients with Vav1-deficient common variable immunodeficiency with T-cell defectsNagaja Capitani, Amedeo Amedei, Silvia Rossi Paccani, et al.
European Journal of Heart Failure|July 11, 2006
Tako-Tsubo-like syndrome during anaphylactic reactionAlessandra Vultaggio, Andrea Matucci, Stefano Del Pace, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|February 3, 2022
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experienceAndrea Matucci, Emanuele Vivarelli, Susanna Bormioli, et al.
Frontiers in Immunology|June 14, 2018
Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's SyndromeAndrea Matucci, Francesco Liotta, Emanuele Vivarelli, et al.
Pageof 14